Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R&M SCCHN) (EXTREME).

被引：0
|
作者：
Vermorken, J. B.
Mesia, R.
Vega-Villegas, M. E.
Remenar, E.
Hitt, R.
Kawecki, A.
Rottey, S.
Zabolotnyy, D.
Erfan, J.
Amellal, N.
Antwerpen, U. Z.
机构：
[1] UZ Antwerpen, Edegem, Belgium
[2] Hosp Duran I Reynals Inst Catala Oncol, Barcelona, Spain
[3] Hosp Univ Marques Valdecilla, Santander, Spain
[4] Orszagos Onkol Intezet, Budapest, Hungary
[5] Hosp 12 Octubre, E-28041 Madrid, Spain
[6] Klin Nowotworow Glowy & Szyi, Warsaw, Poland
[7] UZ Gent, Ghent, Belgium
[8] Inst Otolaringol AMS Ukraine, Kiev, Ukraine
[9] Szalbolcs Szatmar Bereg Megyei Josa Andras Korhaz, Nyiregyhaza, Hungary
[10] Merck KGaA, Darmstadt, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：289S / 289S
页数：1
相关论文
共 50 条
  • [31] Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck
    Machiels, Jean-Pascal
    Kaminsky, Marie-Christine
    Keller, Ulrich
    Bruemmendorf, Tim H.
    Goddemeier, Thomas
    Forssmann, Ulf
    Delord, Jean-Pierre
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (05) : 1207 - 1216
  • [32] Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck
    Jean-Pascal Machiels
    Marie-Christine Kaminsky
    Ulrich Keller
    Tim H. Brümmendorf
    Thomas Goddemeier
    Ulf Forssmann
    Jean-Pierre Delord
    Investigational New Drugs, 2013, 31 : 1207 - 1216
  • [33] Combination of 5-fluorouracil (5-FU) and cisplatin (P) as chemotherapy for carcinomas in head and neck regions
    Salgado, M
    García-Mata, J
    Fírvida, JL
    Rodríguez, MR
    Montanos, MJ
    1ST WORLD CONGRESS ON HEAD AND NECK ONCOLOGY, 1998, : 975 - 979
  • [34] Induction Chemotherapy With 5-Fluorouracil, Cisplatin, and Cetuximab in Advanced Head and Neck Squamous Cell Carcinoma
    Yamauchi, Moriyasu
    Minesaki, Akimichi
    Ishida, Tomoya
    Sato, Yuki
    Okamura, Seiji
    Shuto, Hiroyuki
    Tanaka, Nariyuki
    Hatayama, Eriko
    Shibamiya, Natsuko
    Kuratomi, Yuichiro
    IN VIVO, 2023, 37 (03): : 1275 - 1280
  • [35] TREATMENT OF SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK WITH CISPLATIN AND 5-FLUOROURACIL
    AMREIN, PC
    WIETZMAN, SA
    JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (12) : 1632 - 1639
  • [36] Cilengitide with cetuximab, cisplatin, and 5-FU in recurrent and/or metastatic squamous cell cancer of the head and neck: the phase II ADVANTAGE trial
    Gauler, T. C.
    Clement, P. M.
    Peyrade, F.
    Krauss, J.
    Mesia, R.
    Remenar, E.
    Keilholz, U.
    Delord, J. P.
    Schafhausen, P.
    Erfan, J.
    Brummendorf, T. H.
    Iglesias, L.
    Bethe, U.
    Hicking, C.
    Vermorken, J. B.
    ONKOLOGIE, 2012, 35 : 193 - 194
  • [37] CETUXIMAB PLUS PLATINUM-BASED THERAPY FIRST-LINE IN PATIENTS WITH RECURRENT/METASTATIC (R/M) SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN): A QUALITY OF LIFE (QOL) ANALYSIS OF THE EXTREME TRIAL
    Herrero, F. Rivera
    Hitt, R.
    Kawecki, A.
    Rottey, S.
    Peyrade, F.
    Vynnychenko, I.
    Curran, D.
    Kisker, O.
    Gross, A.
    Vermorken, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 219 - 219
  • [38] Cilengitide with cetuximab, cisplatin, and 5-FU in recurrent and/or metastatic squamous cell cancer of the head and neck: The ADVANTAGE phase II trial
    Vermorken, Jan Baptist
    Peyrade, Frederic
    Krauss, Juergen
    Mesia, Ricard
    Remenar, Eva
    Gauler, Thomas C.
    Keilholz, Ulrich
    Delord, Jean-Pierre
    Schafhausen, Philippe
    Erfan, Jozsef
    Brummendorf, Tim H.
    Iglesias, Lara
    Bethe, Ullrich
    de La Bourdonnaye, Guillaume
    Clement, Paul M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [39] Phase I-II study with docetaxel (D), cisplatin (C) and 5-Fluorouracil (5-FU) in patients with locally advanced inoperable squamous cell carcinoma of the head and neck (SCCHN)
    Schrijvers, D
    Van Herpen, C
    Kerger, J
    Joosens, E
    Brandely, M
    Vermorken, JB
    ANNALS OF ONCOLOGY, 1998, 9 : 75 - 75
  • [40] Biweekly cetuximab in combination with platinum and 5-fluorouracil in metastatic head and neck carcinoma
    Surmeli, Zeki G.
    Ozveren, Ahmet
    Arslan, Cagatay
    Degirmenci, Mustafa
    Karaca, Burcak
    Uslu, Ruchan
    INDIAN JOURNAL OF CANCER, 2019, 56 (01) : 4 - 8
12345